{
  "docId": "019de073-ce1e-74cc-9870-b1827d8467a5",
  "docSlug": "ce894072ac0bdbdb4be0c6e520599e56",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 31 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 31,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a matrix-like structure to compare drug capabilities against specific clinical requirements.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ce1e-74cc-9870-b1827d8467a5/5",
  "deckHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5",
  "deckJsonHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5.json",
  "deckAnchorHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.86,
        "x": 0.07,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "ROS1+, ROS1-positive; CNS, central nervous system; NCCN, National Comprehensive Cancer Network®; NSCLC, non-small cell lung cancer. Sources: Drilon et al., Nat. Rev. Clin. Oncol. 2021; Jordan et al., Cancer Discovery. 2017; Patil et al., J. Thorac. Oncol. 2018; Gainor et al., JCO Precision Oncol. 2017; Lin et al., CCR 2021; Cocco et al., Nat. Rev. Clin. Oncol. 2018; Drilon et al., Lancet Oncol. 2020; Doebele et al., Ann. Oncol. 2019; Shaw et al., NEJM 2020; Li et al., JCO 2022; Drilon et al., Ann. Oncol. 2019; Papadopoulos et al., Clin Cancer Res. 2020; crizotinib prescribing information; entrectinib prescribing information.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3088e447-4bf4-427e-830e-ea1294fc74e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.86,
        "x": 0.07,
        "y": 0.2
      },
      "kind": "table",
      "text": "Comparison matrix of ROS1 inhibitors (Crizotinib, Entrectinib, Lorlatinib, Taletrectinib, Repotrectinib) vs NVL-520 goal across 4 medical needs.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "abd7c3c2-b512-4df6-ab72-dd927a8aa602",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.1
      },
      "kind": "title",
      "text": "NVL-520 | A Rationally Designed Kinase Inhibitor for ROS1",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "482533c5-e892-4b11-8d8d-620d5acd01b0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "87fcd352-2643-4d47-a430-ecaab122db76",
      "evidence": "The slide compares a new drug candidate against established competitors across specific criteria.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}